Tumor Biology

, Volume 35, Issue 6, pp 5205–5212 | Cite as

Tea consumption and leukemia risk: a meta-analysis

  • Shanliang Zhong
  • Zhiyuan Chen
  • Xinnian Yu
  • Weixian Chen
  • Mengmeng Lv
  • Tengfei Ma
  • Jianhua ZhaoEmail author
Research Article


Epidemiologic findings concerning the association between tea consumption and leukemia risk yielded mixed results. We aimed to investigate the association by performing a meta-analysis of all available studies. One cohort studies and six case-control studies with 1,019 cases were identified using PubMed, Web of Science, and EMBASE. We computed summary relative risks (RRs) and 95 % confidence intervals (CIs) using random effect model applied to the relative risk associated with ever, moderate, or highest drinkers vs. non/lowest drinkers. Subgroup analyses were performed based on country (China and USA). Compared with non/lowest drinkers, the combined RR for ever drinkers was 0.76 (95 % CI = 0.65–0.89). In subgroup analyses, significant inverse associations were found for both China and USA studies. The summary RR was 0.57 (95 % CI = 0.41–0.78) for highest drinkers. Same results were only found in China studies. No significant associations were found for moderate drinkers in overall analysis or in subgroup analyses. There was some evidence of publication bias. In conclusion, this meta-analysis suggests a significant inverse association of high tea consumption and leukemia risk. Results should be interpreted cautiously given the potential publication bias.


Cancer risk Diet Epidemiology 



This study was supported by the National Natural Science Foundation of China (81272470).


  1. 1.
    American Cancer Society. Global cancer facts & figures 2nd edition. Atlanta: American cancer society; 2011.Google Scholar
  2. 2.
    Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, Kosary CL YM, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis D, Chen H, Feuer E, Cronin Ke: Seer cancer statistics review, 1975-2010, National Cancer Institute. Bethesda, md, http://seer.Cancer.Gov/csr/1975_2010/, based on November 2012 seer data submission, posted to the seer web site, 2013
  3. 3.
    Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55.CrossRefPubMedGoogle Scholar
  4. 4.
    Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA J Am Med Assoc. 2006;296:1255–65.CrossRefGoogle Scholar
  5. 5.
    Smith DM, Dou QP. Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med. 2001;7:645–52.PubMedGoogle Scholar
  6. 6.
    Ohata M, Koyama Y, Suzuki T, Hayakawa S, Saeki K, Nakamura Y, et al. Effects of tea constituents on cell cycle progression of human leukemia u937 cells. Biomed Res (Tokyo, Japan). 2005;26:1–7.CrossRefGoogle Scholar
  7. 7.
    Han DH, Jeong JH, Kim JH. Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia hl-60 cells. Anticancer Res. 2009;29:1417–21.PubMedGoogle Scholar
  8. 8.
    Iwasaki R, Ito K, Ishida T, Hamanoue M, Adachi S, Watanabe T, et al. Catechin, green tea component, causes caspase-independent necrosis-like cell death in chronic myelogenous leukemia. Cancer Sci. 2009;100:349–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Wu L, Zhou YP, Zhong HJ. A case-control study on the risk factors of leukemia in mining areas of rare-earth in South Jiangxi. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2003;24:879–82.PubMedGoogle Scholar
  10. 10.
    Li Y, Moysich KB, Baer MR, Weiss JR, Brasure J, Graham S, et al. Intakes of selected food groups and beverages and adult acute myeloid leukemia. Leuk Res. 2006;30:1507–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang M, Zhao X, Zhang X, Holman CD. Possible protective effect of green tea intake on risk of adult leukaemia. Br J Cancer. 2008;98:168–70.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Kuo YC, Yu CL, Liu CY, Wang SF, Pan PC, Wu MT, et al. A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Cause Control. 2009;20:57–65.CrossRefGoogle Scholar
  13. 13.
    Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, et al. Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC Cancer. 2009;9:15.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, et al. Diet, lifestyle, and acute myeloid leukemia in the nih-aarp cohort. Am J Epidemiol. 2010;171:312–22.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Li L, Zhang M, Holman D. Population versus hospital controls for case-control studies on cancers in Chinese hospitals. BMC Med Res Methodol. 2011;11:167.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Wells G, Shea B, O’Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. 2010
  17. 17.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMedGoogle Scholar
  18. 18.
    Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods. 2001;6:203–17.CrossRefPubMedGoogle Scholar
  19. 19.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Whitehead A. A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials. Stat Med. 1997;16:2901–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003;361:567–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Naganuma T, Kuriyama S, Kakizaki M, Sone T, Nakaya N, Ohmori-Matsuda K, et al. Green tea consumption and hematologic malignancies in Japan. Am J Epidemiol. 2009;170:730–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang XD, Zhao XY, Zhang M, Liang Y, Xu XH, D'Arcy C, et al. A case-control study on green tea consumption and the risk of adult leukemia. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2008;29:290–3.PubMedGoogle Scholar
  27. 27.
    Sturgeon JL, Williams M, van Servellen G. Efficacy of green tea in the prevention of cancers. Nurs Health Sci. 2009;11:436–46.CrossRefPubMedGoogle Scholar
  28. 28.
    Yuan JM, Sun C, Butler LM. Tea and cancer prevention: epidemiological studies. Pharmacol Res. 2011;64:123–35.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Pastore RL, Fratellone P. Potential health benefits of green tea (Camellia sinensis): a narrative review. Explore (New York, NY). 2006;2:531–9.CrossRefGoogle Scholar
  30. 30.
    Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigallocatechin-3-gallate (egcg) as adjuvant in cancer therapy. Clin Nutr. 2013;32:894–903.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. Vegf receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (egcg), in b-cell chronic lymphocytic leukemia. Blood. 2004;104:788–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Britschgi A, Simon HU, Tobler A, Fey MF, Tschan MP. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2. Br J Haematol. 2010;149:55–64.CrossRefPubMedGoogle Scholar
  33. 33.
    Nakagawa H, Hasumi K, Woo JT, Nagai K, Wachi M. Generation of hydrogen peroxide primarily contributes to the induction of fe(ii)-dependent apoptosis in jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis. 2004;25:1567–74.CrossRefPubMedGoogle Scholar
  34. 34.
    Shim JH, Choi HS, Pugliese A, Lee SY, Chae JI, Choi BY, et al. (-)-epigallocatechin gallate regulates cd3-mediated t cell receptor signaling in leukemia through the inhibition of zap-70 kinase. J Biol Chem. 2008;283:28370–9.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Kawai Y, Matsui Y, Kondo H, Morinaga H, Uchida K, Miyoshi N, et al. Galloylated catechins as potent inhibitors of hypochlorous acid-induced DNA damage. Chem Res Toxicol. 2008;21:1407–14.CrossRefPubMedGoogle Scholar
  36. 36.
    Lopez-Lazaro M, Calderon-Montano JM, Burgos-Moron E, Austin CA. Green tea constituents (-)-epigallocatechin-3-gallate (egcg) and gallic acid induce topoisomerase i- and topoisomerase ii-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide. Mutagenesis. 2011;26:489–98.CrossRefPubMedGoogle Scholar
  37. 37.
    Hazawa M, Takahashi K, Sugata S, Kashiwakura I. (-)-epigallocatechin-3-o-gallate induces nonapoptotic cell death in leukemia cells independent of the 67 kda laminin receptor. J Nat Prod. 2011;74:695–700.CrossRefPubMedGoogle Scholar
  38. 38.
    Fan LP, Shen JZ, Fu HY, Zhou HR, Shen SF, Yu AF. Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line u937 and its relevant mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:286–90.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Shanliang Zhong
    • 1
  • Zhiyuan Chen
    • 2
  • Xinnian Yu
    • 3
  • Weixian Chen
    • 4
  • Mengmeng Lv
    • 4
  • Tengfei Ma
    • 1
  • Jianhua Zhao
    • 1
    Email author
  1. 1.Center of Clinical Laboratory ScienceJiangsu Cancer Hospital Affiliated to Nanjing Medical UniversityNanjingChina
  2. 2.Department of General SurgeryThe Affiliated Hospital of Xuzhou Medical CollegeXuzhouChina
  3. 3.Department of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical SchoolSoutheast UniversityNanjingChina
  4. 4.The Fourth Clinical College of Nanjing Medical UniversityNanjingChina

Personalised recommendations